Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.72 |
| ▸ | SRC | P12931 | 7/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.63 |
| ▸ | RAF1 | P04049 | 2/20 | 0.62 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 6/20 | 0.58 |
| ▸ | MET | P08581 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | HGF | P14210 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | TEK | Q02763 | 1/20 | 0.55 |
| ▸ | MST1R | Q04912 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447835 | 0.91 | MAP2K1 (0.64) | MAP2K1SRCFGFR2RAF1MAPK3 | |
| SCHEMBL4445567 | 0.89 | SRC (0.62) | MAP2K1SRCFGFR2RAF1MAPK3 | |
| SCHEMBL14040784 | 0.86 | MAP2K1 (0.79) | MAP2K1SRCFGFR2RAF1MAPK3 | |
| SCHEMBL4558340 | 0.85 | MAP2K1 (0.71) | MAP2K1SRCFGFR2RAF1MAPK3 | |
| SCHEMBL6993386 | 0.84 | MAP2K1 (1.00) | MAP2K1SRCRAF1MAPK3MAPK1 | |
| SCHEMBL18828353 | 0.83 | SRC (0.57) | MAP2K1SRCFGFR2KDRMET | |
| SCHEMBL4557892 | 0.83 | MAP2K1 (0.73) | MAP2K1SRCFGFR2KDRMET | |
| SCHEMBL4557789 | 0.83 | MAP2K1 (0.73) | MAP2K1SRCFGFR2KDRMET | |
| SCHEMBL12308286 | 0.82 | EGFR (0.77) | SRCKDRMETEGFRAXL | |
| SCHEMBL27731209 | 0.82 | KDR (0.62) | SRCKDRMETEGFRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | MAP2K1 840/4885SRC 9/4885FGFR2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.